Lung cancer drug Palbociclib failed to meet a specified endpoint in a Phase 2 study, reports Healio. 

Fifty-three patients – 17 of whom received docetaxel – enrolled in the study. Eighty-three percent of patients presented with a CCND1 amplification, 13% had a CCND2 amplification, 9% presented with CCND3 and 6% had CDK4.

Five patients in the palbociclib arm (n = 37) were deemed ineligible for evaluation.

Two partial responses were identified among the 32 eligible patients (median age, 67; range 53-81 years; 21 male).

Thirty-eight percent of patients had a standard deviation and the disease control rate was 44%. Median PFS was 1.7 months.

One patient within the partial response arm has progressed with a duration of response of 7.7 months. Four patients reported a grade 4 adverse event and 13 others reported experiencing a grade 3 treatment-related adverse event.